Climb Bio, Inc.
CLYM · Nasdaq · United States
Share price · CLYM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CLYM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+16.0%
- 26 Oct 2026-13.5%
- 26 Aug 2026-9.9%
Nothing announced by CLYM that day or the session before.
- 14 Aug 2026+10.9%
- 6 Aug 2026+12.3%
- 1 Jun 2026+7.7%
Nothing announced by CLYM that day or the session before.
- 5 May 2026+18.2%
- 9 Apr 2026+13.4%
Nothing announced by CLYM that day or the session before.
- 16 Dec 2025+21.3%
Nothing announced by CLYM that day or the session before.
- 15 Dec 2025+27.0%
Nothing announced by CLYM that day or the session before.
Share of unusual movement by asset
For each asset, the share of CLYM's own-move activity since 27 Sep 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
budoprutugevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 4% |
| Other company news (earnings, financing, releases naming no asset) | — | 20% |
| Sessions with no dated event | — | 76% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CD19Monoclonal antibody | Systemic Lupus ErythematosusPrimary Membranous Nephropathy |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $11M | $40M+ $166M short-term inv. | $15M-$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $9.7M | $44M+ $139M short-term inv. | $14M-$11M operating cash flow | report ↗ |
| 2026-Q1 | — | $9.4M | $8.4M+ $101M short-term inv. | $14M-$14M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.1M | $26M+ $61M short-term inv. | $13M-$12M operating cash flow | report ↗ |
| 2025-Q2 | — | $6.6M | $23M+ $62M short-term inv. | $8.7M-$11M operating cash flow | report ↗ |
| 2025-Q1 | — | $17M | $29M+ $69M short-term inv. | $21M-$15M operating cash flow | report ↗ |
| 2024-Q3 | — | $6.1M | $146M+ $47M short-term inv. | $8.9M-$7.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.1M | $223M+ $0 short-term inv. | $55M-$0.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.1M | $105M+ $0 short-term inv. | $1.7M-$1.8M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.9M | $57M+ $50M short-term inv. | $4.0M$3.5M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.7M | $25M+ $77M short-term inv. | $5.2M-$8.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.7M | $34M+ $75M short-term inv. | $22M-$15M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.3M | $36M+ $87M short-term inv. | $9.7M-$4.2M operating cash flow | report ↗ |
| 2022-Q2 | — | $8.7M | $33M+ $90M short-term inv. | $15M-$14M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.1M | $32M+ $92M short-term inv. | $13M-$11M operating cash flow | report ↗ |
| 2021-Q3 | — | $5.7M | $63M+ $83M short-term inv. | $9.6M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $47M | $36M+ $65M short-term inv. | $15M-$54M operating cash flow | report ↗ |
Climb Bio reported full-year 2025 results with no revenue disclosed. R&D spend was $46.71M, up 229.4% YoY from $14.18M, and cash, cash equivalents, and marketable securities totaled $160.7M as of December 31, 2025. The company recorded a net loss of $59.85M for the year.
Management guided that cash is expected to fund operations into 2028. Dosing completed in the Phase 1 study of the budoprutug subcutaneous formulation, with data expected in H1 2026; budoprutug trials in pMN, ITP, and SLE are ongoing, with initial data expected in H2 2026. Enrollment continues in the CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026, and a China SLE study is expected to dose its first patient in H1 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $14M | $87M+ $64M short-term inv. | $18M-$16M operating cash flow | report ↗ |
| 2023-FY | — | $15M | $93M+ $14M short-term inv. | $8.8M-$21M operating cash flow | report ↗ |
| 2022-FY | — | $26M | $44M+ $80M short-term inv. | $11M-$37M operating cash flow | report ↗ |
| 2021-FY | — | $22M | $47M+ $90M short-term inv. | $12M-$36M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($780K), 6 sales ($2.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise | 10,000 | $3.46 | $35K | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise | 10,000 | $3.00 | $30K | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise | 10,000 | $7.89 | $79K | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise | 40,000 | $1.29 | $52K | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director; director; director; director, 10% owner; director, 10% owner | Option exercise (derivative) | 40,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 80 reporting institutions held 32.3M shares ($207.8M, 55.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11,300,939 | $77.4M |
| 2 | MPM BIOIMPACT LLC | 2,593,439 | $17.8M |
| 3 | BRAIDWELL LP | 1,529,675 | $10.5M |
| 4 | GREAT POINT PARTNERS LLC | 1,334,130 | $9.1M |
| 5 | MILLENNIUM MANAGEMENT LLC | 1,276,260 | $8.7M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,178,659 | $8.1M |
| 7 | Kynam Capital Management, LP | 1,003,341 | $6.9M |
| 8 | MARSHALL WACE, LLP | 773,123 | $5.3M |
| 9 | Affinity Asset Advisors, LLC | 700,000 | $4.8M |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 684,908 | $4.7M |
| 11 | Driehaus Capital Management LLC | 600,946 | $4.1M |
| 12 | ADAR1 Capital Management, LLC | 597,662 | $4.1M |
| 13 | NAN FUNG TRINITY (HK) LTD | 420,517 | $2.9M |
| 14 | SPHERA FUNDS MANAGEMENT LTD. | 419,247 | $2.9M |
| 15 | BlackRock, Inc. | 401,649 | $2.8M |